Abstract library

20 results for "vitamin D".
#2772 Vitamin Supplementation and a Personalized Diet in Patients with Neuroendocrine Tumors: The DIVIT Study
Introduction: Patients with neuroendocrine tumors (NETs) are at risk for vitamin deficiencies and poor nutritional status due to excessive serotonin production, diarrhea, previous gastrointestinal surgery, and/or treatment with somatostatin analogues (SSA). Little knowledge exists about vitamin deficiency and how patients should be supported for the deficiencies they develop during their long-lasting disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Johannes Stelwagen
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue
Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Maria Rinzivillo
#256 Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
Introduction: Bone mineral density (BMD) and fractures are influenced by diet, activity, drugs and hormones. Recent studies highlight an inverse relationship between serotonin and BMD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#415 Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
Introduction: A phase II study was designed to assess the activity and safety of metronomic oral capecitabine, bevacizumab, and octreotide (Xelbevoct) in metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). We also assessed the predictive role for progression free survival (PFS) of hypertension, proteinuria and vascular endothelial growth factor (VEGF) polymorphisms and the predictive role of vitamin D on proteinuria and PFS.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi
Keywords: bevacizumab
#463 Primary Neuroendocrine Tumor of the Parathyroid
Introduction: Parathyroids are derived from third and fourth branchial pouches and neuroendocrine C-cells originate for neighboring fifth branchial pouch. A close ontogenic relation between these embryonal pouches is illustrated in DiGeorge syndrome wherein there is an absence of parathyroid glands and C-cells. It is not known for certain if normal parathyroids contain NE cells. However, NETs of the parathyroid have been reported in two other cases (Medline search: 1966-2011).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, ...
Keywords: parathyroid NET
#533 Gastric Neuroendocrine Tumor Type 1 Associated with Autoimmune Polyglandular Syndrome Type 3B: A Case Report
Introduction: Gastric neuroendocrine tumors (GNET) are most commonly associated with pernicious anemia and hypergastrinemia. The coexistence with other endocrinological deficiencies is uncommon.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Ivan Kruljac
#723 The Calcium Metabolism Disturbances 40 Patients with Neuroendocrine Tumors: A Cross-Sectional Study
Introduction: Bone diseases associated with NET are due to genetic background, NET evolution, or they are incidental.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Catalina Poiana
Authors: Poiana C, Carsote M, Dusceac R, Muler M, ...
Keywords: PTH, calcium
#744 Bio-Differentiating and Antiangiogenic Therapy with Gastroenteropancreatic Patients with Neuroendocrine Tumors (GEP-NETs)
Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Others
Presenting Author: MD Lubos Holubec
Authors: Holubec L, Finek J, Fiala O, Matejka V, ...
#830 The Predictive Value of Gastrin Levels for the Diagnosis of Gastric Enterochromaffin-like Cells Hyperplasia, in Patients with Hashimoto’s Thyroiditis
Introduction: Gastrin and chromogranin A (CgA) levels have been tested for the diagnosis of enterochromaffin-like cell hyperplasia (ECLH), in patients with type 1 diabetes and autoimmune atrophic gastritis but there are no data for patients with Hashimoto's thyroiditis (HT).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Dimitrios Thomas